Med-Fine Capital

Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment.

BV Laser is a manufacturer of medical beauty equipment.

ZD Medical is a developer of advanced medical imaging technology focused on improving the diagnosis and treatment of retinal conditions. The company specializes in phase variance optical coherence tomography, a non-invasive tool that enables the simultaneous detection of macular degeneration and retinal microvascular proliferation related to diabetes. This innovative approach provides healthcare professionals with essential insights for the early identification of diabetic retinopathy. ZD Medical combines expertise from both domestic and international scientific and technological professionals to design and manufacture high-quality medical devices. The organization is committed to delivering effective solutions for medical diagnosis and clinical treatment, ultimately aiming to enhance healthcare outcomes and contribute positively to global health initiatives.

PuJu Biotech focuses on developing an engineering process platform for bioactive filling materials and is dedicated to continuously launching world-class high-end regenerative medicine material products to benefit the vast number of people seeking beauty, as well as providing new material solutions for medical beauty and anti-aging for all age groups.

Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."

Rebecca is committed to the application of precision-controlled MEMS radio frequency technology in clinical disease control and rehabilitation. Its core technology comes from the core team's many years of experience and achievements in research and development and productization at the University of California, Fortune 500 medical equipment, and electronic equipment companies. The company cooperated with domestic university research institutes and many top three hospitals in Beijing, Shanghai, and Hangzhou to independently develop micro-radio frequency technology that surpassed similar products in Europe and America. It focuses on delivering innovative medical solutions to the hands of professional caregivers. Rebecca's team possesses technical expertise in micro-devices, RF, and device integration through years of field practice in micro-electronics and clinical innovation.

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

Med-Vision is a developer of virtual reality-based therapy solutions aimed at enhancing medical care services. The company focuses on providing immersive psychotherapy, psychological rehabilitation, and mental health support, particularly for elderly patients. By integrating clinical treatment technology with virtual reality, Med-Vision creates highly engaging simulations that assist healthcare providers in formulating precise treatment plans. In addition to mental health services, the company offers comprehensive health management solutions for post-treatment care, utilizing gamified digital features to support physical rehabilitation and cognitive therapies in hospitals and rehabilitation centers.

VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.

Leadinno Medical Valley is a company that specializes in the production of medical devices aimed at neuroregulatory functions. It develops implantable neuroelectric stimulation products intended to treat various neurological functional diseases. The company emphasizes the use of innovative technologies to create wireless energy-carrying devices, which are designed to enhance patient comfort while simultaneously lowering treatment costs. By focusing on these advancements, Leadinno Medical Valley aims to improve the quality of care for individuals with neurological conditions.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Weimi Bio-Tech is a developer of advanced in vitro diagnostic products that specialize in immunofluorescence chromatography. The company's offerings are primarily focused on inflammation detection, prenatal testing, cervical cancer diagnosis, and cardio-cerebral-vascular testing. Weimi Bio-Tech aims to provide reliable and effective solutions for medical laboratories, enhancing the accuracy and efficiency of point-of-care testing for medical practitioners. Through its innovative products, the company seeks to improve diagnostic capabilities in various medical fields.

Med-Vision is a developer of virtual reality-based therapy solutions aimed at enhancing medical care services. The company focuses on providing immersive psychotherapy, psychological rehabilitation, and mental health support, particularly for elderly patients. By integrating clinical treatment technology with virtual reality, Med-Vision creates highly engaging simulations that assist healthcare providers in formulating precise treatment plans. In addition to mental health services, the company offers comprehensive health management solutions for post-treatment care, utilizing gamified digital features to support physical rehabilitation and cognitive therapies in hospitals and rehabilitation centers.

CorrGene is an innovative company focusing on the research and development and production of new anti-cancer drugs and rare diseases with gene editing technology and cell therapy. The company was established by a group of cell and gene therapy experts, virologists, oncologists, hematologists and biopharmaceutical industry veterans. CorrGene was established in January, 2022 in Jiangsu, China.

Westlake Omics is a biotechnology company based in Hangzhou, Zhejiang, China, founded in 2020. The company specializes in mass spectrometry-based proteomics and other Omics technologies to meet critical clinical needs. Its primary focus is on advancing precision medicine and drug research and development through AI-driven high-throughput proteomic analysis of small clinical specimens. Westlake Omics aims to enhance clinical diagnostics, particularly in tumor detection, by providing reliable and innovative products that leverage technological advancements and multi-modal big data.

AccuPulse specializes in the development of advanced pulsed electric field ablation (PFA) systems designed for the treatment of atrial fibrillation (A-fib). The company focuses on creating innovative PFA generators and specialized catheters that serve as a comprehensive solution for the pulse ablation of A-fib and tumors. By integrating technologies that enhance catheter localization and signal acquisition, AccuPulse provides a more efficient and intelligent alternative to traditional interventional therapies, including radio frequency and cryotherapy. This approach aims to improve outcomes for both healthcare providers and patients by offering a more effective treatment option.

Allorion Therapeutics is a small molecule therapeutic development company specializing in the treatment of cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, Allorion focuses on creating mutant selective and isoform-specific drugs through innovative methods targeting established medical challenges. By concentrating on enhancing drug efficacy and preventing resistance in patients, the company aims to improve therapeutic outcomes in these critical areas of healthcare.

PharmaLegacy Laboratories (Shanghai) Co., Ltd. is a preclinical contract research organization based in Shanghai, China, specializing in pharmacology services. The company focuses on areas such as bone metabolism, immune diseases, inflammation, oncology, orthopaedics, and tissue engineering. It offers a comprehensive range of services that includes specialty pharmacology models, bioimaging, bioanalytical and biomarker analysis, biomechanics, and pathology, as well as report preparation and consulting. PharmaLegacy also conducts studies related to pharmacokinetics, pharmacodynamics, absorption, distribution, metabolism, and excretion, as well as molecular pharmacology and preliminary toxicology assessments. The organization serves a diverse clientele, including multinational pharmaceutical and medical device companies, along with small to medium-sized biotech firms. Established in 2008, PharmaLegacy has forged a strategic partnership with Human Metabolome Technologies, Inc. to enhance its research capabilities.

Epintek is a company focused on the biomedical and medical device sectors, specializing in contract research organization (CRO) services. It offers a range of services including preclinical research, inspection, and testing for medical institutions and equipment manufacturers. By providing integrated regulatory services, Epintek assists clients with registration and clinical trial processes, ensuring reliable and thorough preclinical inspection of medical devices. Its expertise supports the development and compliance of innovative healthcare solutions.

Med-Vision is a developer of virtual reality-based therapy solutions aimed at enhancing medical care services. The company focuses on providing immersive psychotherapy, psychological rehabilitation, and mental health support, particularly for elderly patients. By integrating clinical treatment technology with virtual reality, Med-Vision creates highly engaging simulations that assist healthcare providers in formulating precise treatment plans. In addition to mental health services, the company offers comprehensive health management solutions for post-treatment care, utilizing gamified digital features to support physical rehabilitation and cognitive therapies in hospitals and rehabilitation centers.

Immunophage Biotech, established in 2016, is a Chinese pharmaceutical company dedicated to new drug development. Based in Nanjing, with its R&D center in Shanghai's Pujiang High-Tech Park, the company focuses on creating first-in-class immune-regulating therapies for cancer, autoimmune diseases, and neurodegenerative disorders.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Zhongguancun Shuimu Medical Technology is the operator of a third-party, competent medical device compliance organization. Their business helps companies cut costs and time to market by offering medical device compliance services. It is dedicated to accelerating the registration and listing procedures for new medical device items as well as addressing the issue of how to industrialize creative medical device firms.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Leadinno Medical Valley is a company that specializes in the production of medical devices aimed at neuroregulatory functions. It develops implantable neuroelectric stimulation products intended to treat various neurological functional diseases. The company emphasizes the use of innovative technologies to create wireless energy-carrying devices, which are designed to enhance patient comfort while simultaneously lowering treatment costs. By focusing on these advancements, Leadinno Medical Valley aims to improve the quality of care for individuals with neurological conditions.

Weiyan Medical Technology (Beijing) Co., Ltd. specializes in clinical infectious pathogen detection services, utilizing advanced technology for precise molecular diagnostics. Founded in 2019 and based in Beijing, the company operates an artificial intelligence platform tailored for medical bioinformatics. It employs a range of sequencing technologies, including NovSeq6000 for human genome sequencing, Nextseq550 Dx for diverse applications, Nanopore for pathogen detection, MGISEQ-2000 for optical and biochemical analysis, and Ion GeneStudio S5 for semiconductor sequencing. Additionally, Weiyan Medical provides chemical reagents through its Ion Hi-Q system, enhancing its capabilities in the diagnostics sector.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Artivila Therapeutics is a pharmaceutical company based in Shenzhen, China, founded in 2018. It specializes in the research and development of new drugs, focusing on therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. The company leverages an AI-powered drug discovery engine to create an innovative platform that enables the consistent and efficient development of first-in-class molecules. Artivila Therapeutics aims to enhance patients' lives through advanced biotechnology and targeted therapeutics.

Juncell Therapeutics is a biopharmaceutical company focused on developing innovative therapies for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are then cultivated outside the human body before being reintroduced to patients, aiming to enhance the body's ability to combat tumors while minimizing side effects. Through its research and development efforts, Juncell Therapeutics seeks to advance treatment options in the medical industry, ultimately improving patient outcomes in cancer therapy.

Ultrast is a medical company engaged in the production, and sale of medical platforms and surgical robots.

Commbio Therapeutics focuses on developing genetically engineered bacteria for treating complex diseases in the field of intestine biology.

Allorion Therapeutics is a small molecule therapeutic development company specializing in the treatment of cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, Allorion focuses on creating mutant selective and isoform-specific drugs through innovative methods targeting established medical challenges. By concentrating on enhancing drug efficacy and preventing resistance in patients, the company aims to improve therapeutic outcomes in these critical areas of healthcare.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

PharmaLegacy Laboratories (Shanghai) Co., Ltd. is a preclinical contract research organization based in Shanghai, China, specializing in pharmacology services. The company focuses on areas such as bone metabolism, immune diseases, inflammation, oncology, orthopaedics, and tissue engineering. It offers a comprehensive range of services that includes specialty pharmacology models, bioimaging, bioanalytical and biomarker analysis, biomechanics, and pathology, as well as report preparation and consulting. PharmaLegacy also conducts studies related to pharmacokinetics, pharmacodynamics, absorption, distribution, metabolism, and excretion, as well as molecular pharmacology and preliminary toxicology assessments. The organization serves a diverse clientele, including multinational pharmaceutical and medical device companies, along with small to medium-sized biotech firms. Established in 2008, PharmaLegacy has forged a strategic partnership with Human Metabolome Technologies, Inc. to enhance its research capabilities.

BioNova Pharma biopharmaceutical company that develops and commercializes innovative medicines for cancer and other life-threatening diseases. The company is expanding company with a strong pipeline based on in-house R&D initiatives, partnerships with, and purchases from partners with cutting-edge technology. The goal of BioNova is to close the gap between the high unmet medical needs and the dearth of innovative medicines by developing an innovative R&D platform with a substantial pipeline to address multiple disease areas.

ClinBrain is a company that focuses on healthcare big data services, specifically aimed at hospitals. It has developed a hospital information integration platform that digitizes and standardizes patient data alongside medical and clinical data. This integration is designed to facilitate medical research, improving the efficiency and effectiveness of data management in healthcare settings. By streamlining access to comprehensive patient information, ClinBrain aims to enhance the overall quality of medical research and healthcare delivery.

Shenzhen VitaVitro Biotech Co., Ltd. is a biotechnology company specializing in assisted reproduction technology. Established in 2015 and headquartered in Shenzhen, China, the company offers a comprehensive range of products and services for assisted reproduction laboratories worldwide. Its offerings include cryopreservation solutions, various culture and flushing media, gamete buffer mediums, and labware, all designed to enhance the efficiency and success rates of in vitro fertilization (IVF) procedures. VitaVitro's focus is on addressing infertility challenges by providing integrated solutions that encompass the entire IVF process, from egg retrieval and freezing to embryo culture and transfer, ultimately aiming to optimize embryo quality and increase pregnancy rates for its clients. The company has expanded its presence with offices in Europe, America, and the Asia Pacific region.

Hanyu Medical is a pioneering company in the development, production, and sale of transcatheter mitral valve repair devices. Specializing in minimally invasive treatments for mitral valve regurgitation, the company’s flagship product is the Valve Clamp, an interventional device designed to assist in the closure of heart valves during surgical procedures. By focusing on innovative solutions for heart valve diseases, Hanyu Medical aims to enhance surgical outcomes and patient recovery through its advanced medical technologies.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Zhongyianke Biotech is a company focused on the development and provision of human vaccines. It has successfully launched a flu vaccine and is currently conducting clinical trials for several other vaccines, including a tetravalent influenza vaccine, a tetravalent meningococcal vaccine, a rabies vaccine, and a rubella vaccine. The company holds 14 patents in China, underscoring its innovation in the biotechnology sector. Zhongyianke operates from its headquarters in Tianjin, complemented by a research and development center in Beijing and a production facility located in Liaoning Province.

ChosenMed is a healthcare company specializing in oncology precision medicine, primarily concentrating on early tumor screening and companion diagnosis. The company develops innovative oncology products aimed at the early detection, prevention, and diagnosis of tumors. ChosenMed emphasizes the guidance of targeted medication for solid tumors and the prediction of the efficacy of tumor immunotherapy. By offering a comprehensive suite of precision medical and immunotherapy solutions, the company seeks to enhance patient outcomes in the field of oncology.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Ranok Therapeutics is a biotechnology company specializing in the development of innovative targeted protein degradation technology to facilitate the discovery and development of new therapeutics. This technology engages various biological processes and aims to surpass existing methods in the field. Ranok's research pipeline includes both established and novel drug targets that address cancer and other diseases with considerable unmet medical needs. The company is committed to creating the next generation of cancer therapies that prioritize safety and effectiveness for patients facing serious health challenges.

Tyligand Bioscience (Shanghai) Limited is a biotechnology company established in 2013 and headquartered in Shanghai, China. The company specializes in the development and manufacture of small molecule therapeutics aimed at treating cancer and autoimmune diseases. Tyligand's innovative pharmaceuticals are designed to specifically target tumors and address autoimmune disorders, providing healthcare professionals with effective treatment options to enhance patient outcomes. Through its focus on biochemical pharmaceuticals, Tyligand is committed to advancing therapeutic solutions in the fields of oncology and immunology.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

AMCARELAB is an independent medical service organization providing diagnosis and consultant for hereditary & oncological diseases.

magAssist, founded in 2017 by Dr. Xu Bozhen, is a high-tech enterprise based in Suzhou, specializing in the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular diseases. The company focuses on creating short-term to medium-term ventricular assist devices that are compatible with various blood types. Utilizing advanced fluid mechanics and magnetic suspension technology, magAssist aims to minimize incompatibility issues in patients, thereby enhancing their recovery and treatment processes. The core team consists of leading experts in artificial heart engineering, leveraging extensive experience in research and development to produce domestically manufactured devices with independent intellectual property rights.

Leto Laboratories is a research-focused organization dedicated to advancing the field of protein re-engineering to address unmet medical needs, particularly in cancer and rare diseases. The company utilizes cutting-edge technologies, including high-throughput protein re-screening, purification, and drug formulation development platforms, to facilitate the creation of innovative protein-based therapeutics. With a diverse team of experts, Leto Laboratories aims to enhance the efficacy of protein-based drugs and contribute significantly to the treatment landscape for challenging health conditions.

ZD MedTech specializes in developing advanced robotic assistive technology and intelligent rehabilitation solutions tailored for clinical needs in China. The company's core offerings include high-end rehabilitation robots and exoskeleton upper limb training robots, designed to enhance patient recovery and expedite rehabilitation treatment.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Oceanus Plus is a company based in China that specializes in the development of clinical trial management systems and clinical research products. The organization holds independent intellectual property rights, which allows it to innovate and tailor its offerings to meet the needs of the clinical research industry. Through its focus on enhancing the efficiency and effectiveness of clinical trials, Oceanus Plus aims to improve the overall quality of clinical research processes.

Immvira, established in Shenzhen, China, in May 2015, is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Founded by a team of renowned researchers, including Professors from prestigious institutions, Immvira specializes in biopharmaceutical technology centered on oncolytic viruses and vector-based methods. The company’s flagship product is a genetically engineered Oncolytic Herpes Simplex Virus, designed to target metastatic tumors and those that are difficult to reach through traditional injection methods. By leveraging its advanced biotechnology platform, Immvira aims to improve treatment outcomes for cancer patients, providing effective therapeutic options for challenging tumor types.

Cherubs is a baby formula milk powder manufacturer.

SAFE Pharmaceutical, officially known as Beijing Saifu Medical Research Institute Co., Ltd., operates as a Contract Research Organization (CRO) specializing in pharmaceutical research and development services. The company collaborates with esteemed institutions such as the Shanghai Institute of Materia Medica and the National Drug Safety Evaluation and Research Center, leveraging their expertise to enhance its operational capabilities. With a core team comprised of experienced researchers from prestigious scientific organizations, SAFE Pharmaceutical offers comprehensive services that include R&D consulting, toxicology evaluations, and clinical trial design. This integrated approach allows pharmaceutical developers to efficiently advance their product research and development initiatives, supported by strong technical expertise and management experience in drug development and GLP compliance.

Weimi Bio-Tech is a developer of advanced in vitro diagnostic products that specialize in immunofluorescence chromatography. The company's offerings are primarily focused on inflammation detection, prenatal testing, cervical cancer diagnosis, and cardio-cerebral-vascular testing. Weimi Bio-Tech aims to provide reliable and effective solutions for medical laboratories, enhancing the accuracy and efficiency of point-of-care testing for medical practitioners. Through its innovative products, the company seeks to improve diagnostic capabilities in various medical fields.

Eccogene is a clinical stage biopharmaceutical company focused on developing therapeutic solutions for unmet medical needs, particularly in the areas of metabolic and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science, with the aim of creating innovative pharmaceuticals that target complex chronic conditions such as obesity and diabetes. Eccogene is dedicated to advancing its pipeline of metabolic drugs to enhance patient outcomes and address significant health challenges.

Shunzhi Technology is a Healthcare company.

Gaugene is a high-tech enterprise that specializes in the development and supply of hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. The company offers advanced instruments and reagents that play a critical role in hematology diagnosis, as well as broader clinical diagnostics and life science research. Gaugene is notable for being the only manufacturer in China that incorporates high-power flow lasers and high-sensitivity multi-color fluorescence detection systems in its products. This technological edge enables the company to provide innovative solutions for clinical diagnosis, flow cytometry technology, single cell research, protein screening, and the discovery of new clinical indicators. Gaugene is co-sponsored by experienced professionals from renowned domestic IVD companies, ensuring a strong foundation in industry-leading technologies.

ChosenMed is a healthcare company specializing in oncology precision medicine, primarily concentrating on early tumor screening and companion diagnosis. The company develops innovative oncology products aimed at the early detection, prevention, and diagnosis of tumors. ChosenMed emphasizes the guidance of targeted medication for solid tumors and the prediction of the efficacy of tumor immunotherapy. By offering a comprehensive suite of precision medical and immunotherapy solutions, the company seeks to enhance patient outcomes in the field of oncology.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Julu Medical is a company dedicated to the development of systematic digital rehabilitation technologies aimed at improving the quality of life for patients with cardiac and pulmonary diseases. It specializes in designing and constructing various rehabilitation systems, including those for intensive care, cardiac rehabilitation, and respiratory rehabilitation. Additionally, Julu Medical operates centers focused on the rehabilitation of elderly patients suffering from chronic cardiopulmonary conditions, contributing to a comprehensive approach to patient care and recovery. Through its innovative therapies, the company seeks to enhance the overall rehabilitation experience for individuals with significant health challenges.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Hanyu Medical is a pioneering company in the development, production, and sale of transcatheter mitral valve repair devices. Specializing in minimally invasive treatments for mitral valve regurgitation, the company’s flagship product is the Valve Clamp, an interventional device designed to assist in the closure of heart valves during surgical procedures. By focusing on innovative solutions for heart valve diseases, Hanyu Medical aims to enhance surgical outcomes and patient recovery through its advanced medical technologies.

Beijing GenomePrecision Technology Co., Ltd. is a molecular diagnostic company focused on developing precision medicine tests to enhance the diagnosis and treatment of various diseases, including blood tumors, transplantation needs, and cardiovascular conditions. Established in 2015 and headquartered in Beijing, the company integrates research and development, manufacturing, distribution, and registration of its products. GenomePrecision utilizes advanced molecular technology platforms, such as real-time fluorescence quantitative PCR, Sanger sequencing, high-throughput next-generation sequencing, and capillary electrophoresis, to create a diverse range of diagnostic products. These include tests for leukemia, lymphoma, solid tumors, and pharmacogenomics, as well as tools for organ transplant monitoring and pathogen detection. The company also produces molecular diagnostic kits for targeted drug testing and auxiliary diagnosis of cervical cancer, among other applications. By focusing on clinical diagnosis and treatment requirements, GenomePrecision aims to improve patient outcomes through innovative molecular diagnostics.

Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

Surgnova is a Beijing-based company established in 2015 by Huang Wenxing, specializing in the development of minimally invasive surgery equipment and supplemental robotics for tumor treatment. The company operates a research and development center equipped with over ten laboratories focused on various fields, including electronics, machinery, optics, acoustics, and robotics. Surgnova has created three main platforms: an endoscopy platform, an energy surgery platform, and a tumor ablation platform. These innovations are designed to assist surgeons in performing minimally invasive procedures, leading to quicker treatments and reduced bodily harm for patients. Through its advanced technologies, Surgnova aims to enhance surgical outcomes and improve the overall experience for both healthcare providers and patients globally.

Biosis Healing specializes in regenerative medicine materials and implantable medical devices tailored for clinical surgery. The company offers a range of innovative products designed for minimally invasive procedures, including solutions for hernia repair, abdominal wall surgery, dentistry, and neurosurgery. Among its notable offerings are regenerative surgical bio-materials and implantable soft tissue repair mesh, which assist in the regeneration of tissue defects. One of its key developments is a non-crosslinked Extracellular Matrix bio-material that promotes tissue repair and functional regeneration following surgical resections. Biosis Healing is committed to advancing technology and treatment approaches through collaboration with clinical specialists, continually working to enhance its product lineup and improve surgical outcomes.

Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

Health SAGE provides health services for back and pelvic problems. Health SAGE also provides extra services such as massages, neck and waist assessments, and jiannao head care. Health SAGE was established in 2014 in Shanghai, China.